Edgewise Therapeutics Inc. Common Stock vs Sasol Ltd. American Depositary Shares — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while Sasol Ltd. American Depositary Shares trades at $15.63 (market cap $9.94B). The key difference: Sasol Ltd. American Depositary Shares is far larger — about 2.5× Edgewise Therapeutics Inc. Common Stock's market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, Edgewise Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Sasol Ltd. American Depositary Shares for 2 Days on average.
| EWTX | SSL | |
|---|---|---|
Market Cap | $3.94B | $9.94B |
Volume | 810,104 | 1,412,509 |
Sector | Health | Basic Materials |
52-Week High | $48.35 | $15.63 |
52-Week Low | $14.89 | $5.33 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $3.48B | $13.66B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sasol (SSL) trades at $15.58, up 1.83% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected revenue growth from $249.1B in 2025 to $272.1B in 2026. Recent developments include a sustainable aviation fuel agreement with White Desert and board changes, while the CFO's stock sales warrant monitoring.
SSL presents a compelling value opportunity with attractive valuation multiples (P/E 13.74, EV/EBITDA 5.45) and 73% analyst buy ratings. However, risks include negative cash flow trends and high RSI levels suggesting potential overbought conditions. The stock's upside depends on continued operational improvements and commodity market stability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →